Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Initiator Pharma

3.14 SEK

+4.67 %

Less than 1K followers

INIT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+4.67 %
+2.95 %
-16.93 %
-20.10 %
-54.16 %
-57.28 %
-47.14 %
-23.98 %
-30.00 %

Initiator Pharma is a biotechnology company developing drug candidates for diseases of the central and peripheral nervous system. The company's main business focus is on the development of drug candidates used in the treatment of erectile dysfunction in men. Initiator Pharma was founded through a spin-off from the company Saniona and is headquartered in Denmark.

Read more
Market cap
214.94M SEK
Turnover
195.25K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.2.
2026

Annual report '25

8.5.
2026

Interim report Q1'26

29.5.
2026

General meeting '26

All
Press releases
ShowingAll content types
Press release11/24/2025, 7:56 AM

DNB Carnegie Access: Initiator Pharma: Advancing in vulvodynia – Q3 review

Initiator Pharma
Press release11/21/2025, 3:03 PM

Redeye: Initiator Pharma (Q3 review) - Back in the clinic

Initiator Pharma
Regulatory press release11/21/2025, 8:55 AM

Correction: INITIATOR PHARMA: Q3 2025 REPORT

Initiator Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release11/21/2025, 7:30 AM

INITIATOR PHARMA: Q3 2025 REPORT

Initiator Pharma
Press release11/18/2025, 1:03 PM

BioStock: Video from Initiator Pharma’s presentation at the BioStock Life Science Summit 2025

Initiator Pharma
Press release11/3/2025, 7:30 AM

Initiator Pharma receives UK CTA approval to initiate Phase 2a study in vulvodynia

Initiator Pharma
Press release9/25/2025, 9:49 AM

BioStock: Video from Initiator Pharma’s live interview at BioStock Investing in Life Science – From Seed to Success

Initiator Pharma
Press release9/8/2025, 7:30 AM

Initiator Pharma to present at Nordic Women’s Health Hub 2025

Initiator Pharma
Press release9/3/2025, 11:15 AM

Initiator Pharma applies to initiate Phase 2a study in vulvodynia

Initiator Pharma
Press release8/25/2025, 8:58 AM

DNB Carnegie Access: Initiator Pharma: Study initiation approaching – Q2 review

Initiator Pharma
Press release8/22/2025, 10:57 AM

Redeye: Initiator Pharma Q2 - Financed to explore vulvodynia

Initiator Pharma
Regulatory press release8/22/2025, 6:30 AM

INITIATOR PHARMA: Q2 2025 REPORT

Initiator Pharma
Regulatory press release7/16/2025, 1:45 PM

Initiator Pharma carries out a directed new share issue to guarantors

Initiator Pharma
Press release7/1/2025, 9:10 AM

DNB Carnegie Access: Initiator Pharma: Capital raise completed

Initiator Pharma
Regulatory press release7/1/2025, 6:30 AM

Initiator Pharma announces outcome of rights issue

Initiator Pharma
Regulatory press release6/10/2025, 8:45 AM

Initiator Pharma publishes Memorandum and Disclosure Document regarding the Rights Issue

Initiator Pharma
Regulatory press release6/6/2025, 8:55 AM

Initiator Pharma A/S – Resolutions of the extraordinary general meeting 2025

Initiator Pharma
Regulatory press release5/28/2025, 6:30 AM

Initiator Pharma updates the timeline for the rights issue

Initiator Pharma
Regulatory press release5/23/2025, 9:55 AM

Initiator Pharma A/S – Resolutions of the annual general meeting 2025

Initiator Pharma
Regulatory press release5/22/2025, 6:00 PM

Notice to convene extraordinary general meeting in Initiator Pharma

Initiator Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.